Every Form 4 that Bicycle Therapeutics plc (BCYC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BCYC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCYC filings page.
Bicycle Therapeutics plc (BCYC) Chief Operating Officer Jennifer Scott Perry reported direct sales of 30 ordinary shares on October 5, 2026, at a weighted average price of $3.57 per share; prices ranged from $3.56 to $3.57. The sale was required to cover statutory tax withholding tied to RSU vesting and settlement. She also reported selling 326 ordinary shares at $3.78 per share on October 5, 2026, under a Rule 10b5-1 trading plan.
Bicycle Therapeutics plc director Robert Charles Swanton reported selling 3,431 ordinary shares on October 2, 2026, at a weighted average price of $3.47 per share. The shares were sold to cover statutory tax withholding related to RSU vesting and settlement, as required by his award agreement; the transaction was not discretionary. Swanton directly held 15,782 shares after the sale. No Rule 10b5-1 plan is reported.
Bicycle Therapeutics plc Chief Scientific Officer Michael Skynner reported direct sales of 1,942 Ordinary Shares on October 2, 2026, at a weighted average price of $3.47 per share, and 503 Ordinary Shares on October 5, 2026, at a weighted average price of $3.57 per share. The reported prices reflect transactions within ranges of $3.41 to $3.525 and $3.56 to $3.57, respectively. Both sales covered statutory tax withholding obligations tied to RSU vesting and settlement; the award agreement requires these sell-to-cover transactions, which the footnote says were not discretionary.
Bicycle Therapeutics plc (BCYC) Chief Product & Supply Chain Officer Michael Charles Ferguson Hannay reported two sell-to-cover transactions: 1,572 ordinary shares on October 2, 2026, at a weighted average price of $3.47 per share, and 242 shares on October 5, 2026, at a weighted average price of $3.57 per share. Both transactions were required by his award agreement to cover statutory tax withholding tied to RSU vesting and settlement, rather than being discretionary sales. The October 2 shares sold at prices from $3.41 to $3.525; the October 5 shares sold at prices from $3.56 to $3.57.
Bicycle Therapeutics plc (BCYC) Chief Operating Officer Jennifer Scott Perry reported sales of 1,500 ordinary shares on October 2 and October 5, 2026. She sold 1,094 shares on October 2 at a weighted average price of $3.47 per share, and on October 5 sold 80 shares at a weighted average of $3.56 and 326 shares at $3.78.
The 1,094- and 80-share sales covered statutory tax withholding required in connection with RSU vesting and settlement under her award agreement. The 326-share sale was made under a Rule 10b5-1 trading plan adopted March 27, 2025.
Bicycle Therapeutics plc (BCYC) chief executive officer and director Kevin Lee reported two direct sales of ordinary shares to fund statutory tax withholding on RSUs. On October 2, 2026, he sold 6,167 shares at a weighted average price of $3.47, with sale prices ranging from $3.41 to $3.525. On October 5, 2026, he sold 1,638 shares at a weighted average price of $3.57, with sale prices ranging from $3.56 to $3.57. The award agreement mandated both sell-to-cover transactions; they were not discretionary sales.
Bicycle Therapeutics plc (BCYC) Chief Financial Officer Travis Alvin Thompson reported selling 893 ordinary shares on October 2, 2026, at a weighted-average $3.47 per share, and 79 shares on October 5, 2026, at a weighted-average $3.57 per share. Both were required sell-to-cover transactions to fund minimum statutory tax withholding associated with RSU vesting and settlement under his award agreement; the footnote says they were not discretionary. No Rule 10b5-1 plan is reported.
Bicycle Therapeutics PLC Chief Financial Officer Travis Alvin Thompson received a grant of employee stock options for 60,000 Ordinary Shares on July 15, 2026. The options have an exercise price of $4.2100 per share, expire on July 15, 2036, and vest 25% on July 15, 2027 with the balance in 36 equal monthly installments.
BICYCLE THERAPEUTICS PLC reported that chief product and supply chain officer Michael Charles Ferguson Hannay received an employee stock option grant for 60,000 ordinary shares. The option has an exercise price of 4.21 per share, expires on July 15, 2036, and vests one-fourth on July 15, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter.
Bicycle Therapeutics plc reported that Chief Scientific Officer Michael Skynner received a grant of 60,000 employee stock options on July 15, 2026. These options allow purchase of Ordinary Shares at an exercise price of $4.2100 per share, expire on July 15, 2036, and vest with one-fourth on July 15, 2027 and the remainder in 36 equal monthly installments thereafter.
Bicycle Therapeutics plc reported that Chief Operating Officer Jennifer Scott Perry received an employee stock option grant covering 60,000 Ordinary Shares on July 15, 2026. The option has a $4.21 exercise price, expires July 15, 2036, and vests 25% on July 15, 2027, with the remainder vesting in 36 equal monthly installments.
Bicycle Therapeutics Chief Operating Officer Jennifer Scott Perry reported selling a total of 1,412 Ordinary Shares in open-market transactions on July 2 and July 6, 2026 at prices reported between $4.27 and $4.34 per share. According to the disclosure, these shares were sold to cover statutory tax withholding obligations arising from the vesting and settlement of RSUs under a mandated “sell to cover” arrangement, rather than as discretionary sales. The transactions were carried out under a Rule 10b5-1 trading plan adopted on March 27, 2025, and Perry continues to hold approximately 91,052 Ordinary Shares directly after the reported sales.
Bicycle Therapeutics plc Chief Scientific Officer Michael Skynner reported two small open-market sales of Ordinary Shares tied to tax withholding on vested equity awards. On July 2, 2026, he sold 1,859 shares at a weighted average price of $4.27 per share, followed by 532 shares on July 6, 2026 at a weighted average price of $4.31. A footnote explains these transactions were required "sell to cover" sales to satisfy statutory tax withholding obligations related to RSU vesting and were not discretionary. After these sales, Skynner directly held 157,171 Ordinary Shares.
BICYCLE THERAPEUTICS PLC chief executive Kevin Lee reported two small share sales that were executed solely to cover taxes on vested RSUs. On July 2, 2026, he sold 5,905 ordinary shares at a weighted average price of $4.27 per share, followed by 1,737 shares on July 6, 2026 at a weighted average price of $4.31. A footnote explains these “sell to cover” transactions were mandated by his award agreement to satisfy statutory tax withholding obligations and were not discretionary market sales. After these transactions, Lee directly owns 603,671 ordinary shares, so the 7,642 shares sold represent only a small fraction of his holdings.
BICYCLE THERAPEUTICS PLC executive Michael Charles Ferguson reported small share sales linked to tax withholding on vested RSUs. He sold a total of 1,761 Ordinary Shares in two open-market transactions at weighted average prices of about $4.27 and $4.31 per share. According to the footnotes, these sales were mandated under a "sell to cover" arrangement to satisfy minimum statutory tax obligations from RSU vesting, rather than discretionary trading. After these transactions, he directly holds 94,375 Ordinary Shares.
BICYCLE THERAPEUTICS PLC Chief Financial Officer Travis Alvin Thompson reported the sale of 923 Ordinary Shares in two open-market transactions. The shares were sold at weighted average prices around $4.27 and $4.31 to cover statutory tax withholding obligations on vested RSUs, as required by his award agreement. Following these mandated sell-to-cover transactions, he holds 64,441 Ordinary Shares directly.
Bicycle Therapeutics PLC officer Michael Charles Ferguson reported selling a total of 1,772 Ordinary Shares in two transactions on April 2 and April 6, 2026, at weighted average prices around $4.91 and $5.05 per share.
According to the disclosure, these shares were sold solely to cover statutory tax withholding obligations arising from the vesting and settlement of RSUs under a mandatory “sell to cover” arrangement, rather than as discretionary open‑market sales. After these sales, Ferguson directly holds 96,136 Ordinary Shares.
Bicycle Therapeutics plc Chief Financial Officer Travis Alvin Thompson reported required sales of ordinary shares to cover taxes on vesting RSUs. On April 2, he sold 799 shares at a weighted average price of $4.91, from trades between $4.88 and $4.98. On April 6, he sold 102 shares at $5.05. The filing states these transactions were mandated "sell to cover" sales for statutory tax withholding and were not discretionary. After these sales, he directly holds 65,364 ordinary shares.
Bicycle Therapeutics plc Chief Operating Officer Jennifer Scott Perry sold a total of 1,408 ordinary shares of the company in early April 2026. The sales occurred on April 2 and April 6 at prices around $4.91–$5.05 per share. A portion of the shares was sold to cover statutory tax withholding obligations tied to the vesting and settlement of restricted stock units under a mandatory “sell to cover” arrangement, meaning those shares were not sold at her discretion. The filing also notes that one of the transactions was executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2025. Following these transactions, she directly holds 92,464 ordinary shares.
Bicycle Therapeutics CEO Kevin Lee disposed of 7,683 Ordinary Shares in mandated transactions tied to RSU vesting. The sales, executed as "sell to cover" for statutory tax withholding, occurred at weighted average prices around $4.91 and $5.05 per share. After these transactions, he continues to hold 611,313 Ordinary Shares directly.
Bicycle Therapeutics PLC chief scientific officer Michael Skynner reported small share sales tied to tax withholding on vested RSUs. On two April dates, a total of 2,404 ordinary shares were sold in the open market at weighted average prices around $4.91 and $5.05 per share to cover statutory tax obligations mandated by his award agreement. After these transactions, he continued to hold 159,562 ordinary shares directly.
Bicycle Therapeutics reported that its Chief Financial Officer, Travis Thompson, received a grant of employee stock options on February 3, 2026. The award covers 58,000 options to buy ordinary shares at an exercise price of $6.49 per share.
The options were granted at no cost and are held directly. They vest over time: one-fourth of the total underlying shares vests on February 3, 2027, with the remaining options vesting in 36 equal monthly installments afterward, creating a multi-year retention and incentive structure.
Bicycle Therapeutics chief technology officer Michael Skynner reported new equity awards and related tax-share sales. On January 2, 2026, he received 50,000 restricted share units, each representing one ordinary share at $0, with one-fourth vesting on January 2, 2027 and the rest vesting in 12 equal quarterly installments. He also received an employee stock option for 100,000 ordinary shares at an exercise price of $7.08, vesting one-fourth on January 2, 2027 and the remainder in 36 equal monthly installments.
To cover statutory tax withholding obligations from RSU vesting and settlement, 3,045 ordinary shares were sold on January 2, 2026 at a weighted average price of $6.8 and 3,266 shares were sold on January 5, 2026 at a weighted average price of $6.46, as mandated by his award agreement. After these transactions, he directly owned 161,966 ordinary shares and 100,000 options.
Bicycle Therapeutics director Roger D. Dansey reported new equity awards in the form of ordinary shares and stock options. On January 2, 2026, he received 3,032 ordinary shares as a restricted share unit (RSU) award at a price of $0 per share, bringing his directly held ordinary shares to 15,532.
The RSUs will vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026, with each RSU representing a contingent right to receive one ordinary share. He was also granted a stock option for 6,065 ordinary shares at an exercise price of $7.08, which will vest in four equal installments on the same 2026 dates and will expire on January 2, 2036.
Bicycle Therapeutics director Herve Hoppenot reported equity awards from the company. On January 2, 2026, he received 3,032 ordinary shares in the form of a restricted share unit (RSU) award, with no cash price per share at grant. Each RSU represents the right to receive one ordinary share.
He was also granted a stock option for 6,065 ordinary shares at an exercise price of $7.08 per share. Both the RSUs and the option vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026. After the RSU grant, Hoppenot beneficially owned 15,532 ordinary shares directly, plus the option covering 6,065 shares.
Bicycle Therapeutics plc reported new equity awards to director Janice Bourque. On January 2, 2026, she received 9,500 ordinary shares as a restricted share unit (RSU) award, with the RSUs vesting in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026. Each RSU represents a contingent right to receive one ordinary share.
On the same date, she was also granted a stock option to purchase 19,000 ordinary shares at an exercise price of $7.08 per share, vesting in four equal installments on those same 2026 dates and expiring on January 2, 2036. Following these awards, she beneficially owns 32,500 ordinary shares directly and holds 19,000 stock options.
Bicycle Therapeutics plc reported equity awards linked to funds advised by Baker Bros. Advisors LP. On January 2, 2026, the company granted 19,000 restricted share units (RSUs), each representing one American Depositary Share (ADS) or one ordinary share, and 38,000 share options with a strike price of $7.08, in respect of Felix J. Baker’s service as a director under the 2020 Equity Incentive Plan.
The RSUs and options vest in four equal quarterly installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026, subject to his continued board service. Footnotes state that, under the adviser’s policies, Felix J. Baker does not have any right to these compensation securities; instead, funds including 667, L.P. and Baker Brothers Life Sciences, L.P. have an indirect proportionate pecuniary interest, and Baker Bros. Advisors LP holds voting and dispositive power over the RSUs, options and any ADS or ordinary shares issued from them.